Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its news flow, as reflected in recent press releases and SEC filings, centers on clinical trial progress, scientific publications, financing activities and investor outreach related to its pipeline.
Investors following MNMD news can track updates on MM120, MindMed’s proprietary, pharmaceutically optimized form of lysergide D-tartrate (LSD), which the company is developing for generalized anxiety disorder and major depressive disorder. Recent announcements have highlighted Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD and MDD, as well as the publication of a Phase 2b GAD trial in the Journal of the American Medical Association (JAMA). MindMed also issues news on MM402, its proprietary form of R(−)-MDMA being developed for core symptoms of autism spectrum disorder.
MindMed’s news releases frequently cover financial results, underwritten public offerings of common shares, and the intended use of proceeds to fund research and development and general corporate purposes. The company also announces participation in major healthcare and investor conferences, such as events hosted by J.P. Morgan, Stifel, Jefferies, Evercore and Piper Sandler, and provides details on investor webcasts and corporate presentations.
This MNMD news page aggregates these company-issued updates so readers can review clinical milestones, capital markets transactions, and corporate communications in one place. Regularly reviewing this information can help market participants understand how MindMed reports on the advancement of its brain health pipeline and its interactions with the investment community.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Dr. Sarah Y. Vinson as a director and member of the audit committee, effective immediately. Dr. Vinson is a triple board-certified psychiatrist with significant experience in child and adolescent psychiatry, and she aims to drive innovation in mental health treatments. Her appointment is part of a strategy to enhance board independence and expertise. Dr. Vinson will be nominated for election at the upcoming shareholder meeting on May 27, 2021. This appointment highlights MindMed's commitment to expanding its leadership in the psychedelic medicine sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported financial results for Q1 2021, with total assets of $201 million and a cash balance of $160 million. The company incurred a net loss of $14 million for the quarter, with a cash burn of $10 million. Key business developments include the acquisition of HealthMode, clinical trials for MDMA and LSD, and significant financing efforts totaling $73 million USD and $15.4 million USD. Management will discuss these results in an earnings call on May 17, 2021.
MindMed (NASDAQ: MNMD) has appointed Peter Mack, PhD, as Vice President of Pharmaceutical Development. He will oversee product development across MindMed's portfolio, including LSD and ibogaine derivative 18-MC. Previously, Peter held a senior role at AstraZeneca, contributing to inhalation therapies for respiratory diseases. His dual PhD from Harvard and MIT positions him to strengthen MindMed's development pipeline, focused on psychedelic-inspired medicines for addiction and mental health disorders. CEO J.R. Rahn expressed excitement over Mack's addition to the team.
On May 5, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the launch of Project Angie to advance psychedelics, particularly LSD, for treating pain conditions. The company will initiate a Phase 2a Proof of Concept study, submitting a pre-IND briefing to the FDA in the latter half of 2021. With the global analgesics market projected to grow by over $31 billion by 2030, MindMed seeks to innovate within the pain treatment sector. Preliminary studies indicate psychedelics may offer a novel treatment mechanism for pain relief.
MindMed (Nasdaq: MNMD) has officially commenced trading on The Nasdaq Capital Market as of April 27, 2021. The company's shares previously traded on the OTCQB under the symbol MMEDF and will now be traded under the symbol MNMD. MindMed will also retain its listing on the Neo Exchange under the symbol MMED. The announcement includes a live bell ringing ceremony, highlighting the significance of this transition for the company, which focuses on developing psychedelic-inspired therapies for addiction and mental health.